

**AGC Pharma Chemicals Selected as “Best in Class”  
in Four Categories at the CDMO Leadership Awards 2026**

Tokyo, Japan – April 14, 2026, AGC Pharma Chemicals, the small molecule pharmaceutical CDMO<sup>\*1</sup> division of AGC (AGC Inc., Headquarters: Tokyo; President & CEO: Yoshinori Hirai), has been selected as “Best in Class” in four categories in the Small/Mid-Sized Small Molecule API segment<sup>\*2</sup> at the [CDMO Leadership Awards 2026](#). This marks the second consecutive year that AGC Pharma Chemicals has received this recognition.



The CDMO Leadership Awards are co-hosted by Outsourced Pharma<sup>\*3</sup> and Life Science Connect<sup>\*4</sup>. Award recipients are selected based on evaluations from pharmaceutical and biopharmaceutical companies that have conducted business with CDMOs within the past two years, followed by analysis and validation by the Tufts Center for the Study of Drug Development (Tufts CSDD)<sup>\*5</sup>, an independent third-party research institution.

In this awards program, CDMOs are evaluated from multiple perspectives across the entire lifecycle of pharmaceutical development and manufacturing outsourcing projects, including not only technical capabilities, but also aspects such as project management, team structure, and collaboration with client companies.

The categories in which AGC Pharma Chemicals was selected as “Best in Class,” along with the evaluation highlights, are as follows:

- **Overall Staff**  
Highly specialized personnel providing prompt and accurate responses, supported by a team structure that enables close and seamless collaboration.
- **Cultural Fit**  
Strong partnerships built through close collaboration with client teams and clear, transparent communication.
- **Technology Use**  
Strong execution capability and operational efficiency through the effective application of advanced technologies and systems in development and manufacturing processes.
- **Scaling Support**  
Support for clients’ business growth through flexible responses aligned with transitions from development to commercial scale and expansion of manufacturing capacity.

Within AGC Group’s life science business, CDMO services compliant with cGMP<sup>\*6</sup> standards are provided across three major regions: Japan, the United States, and Europe. AGC supports a wide range of modalities, including small molecule pharmaceuticals and agrochemicals, as well as biopharmaceuticals and gene and cell therapies.

Going forward, under its medium-term management plan “[\*AGC plus-2026\*](#),” AGC Group remains committed to advancing one of its three social values, “Well-being.” By continuing to meet the diverse needs of pharmaceutical and biopharmaceutical companies and strengthening its role as a long-term partner, AGC Group will contribute to safe, secure, and healthy lives for people around the world.

### Notes

\*1 CDMO: Contract Development and Manufacturing Organization

\*2 Small/Mid-Sized Small Molecule API: Small- and mid-sized CDMO segment (companies with annual CDMO revenues of less than USD 1 billion) focused on small-molecule active pharmaceutical ingredients (APIs)

\*3 Official website: <https://www.outsourcedpharma.com/>

\*4 Official website: <https://www.lifescienceconnect.com/>

\*5 Tufts Center for the Study of Drug Development (Tufts CSDD)

\*6 cGMP: current Good Manufacturing Practice

### Related press releases

[AGC Pharma Chemicals Honored in Four Categories at the CDMO Leadership Awards 2026](#)

[AGC Pharma Chemicals named Champion in Small Molecule API at the European CDMO Leadership Awards 2025](#)

### Previous press release

[AGC’s Pharmaceutical CDMO Division Wins Four Awards at the CDMO Leadership Awards 2025](#)